increased count of tumor-specific CD8+ T cells (18/24); activation of Th1 response (12/24); DTH+ response to TAAs in 41% of patients; DTH+ response to KLH in 64% of patients; patient survival rate increased 1.9-fold; partialresponse (1/24); disease stabilization (7/24); disease progression (16/24). This evidence concerns the gene CD8A and neoplasm.